drugset / Trial / NCT00629941

Safety and Efficacy Study of AzaSite® in Subjects With Blepharitis

NCT00629941

Phase 4 Completed 25 enrolled Merck Sharp & Dohme LLC
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of AzaSite® ophthalmic solution, 1% on signs \& symptoms of blepharitis and tear cytokine and eyelid bacterial load levels

Timeline

Start
2008-03
Primary completion
2008-08
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Azithromycin Small molecule Other

Indications